These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 10717018

  • 1. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS.
    N Engl J Med; 2000 Mar 16; 342(11):810-1. PubMed ID: 10717018
    [No Abstract] [Full Text] [Related]

  • 2. Taiwan experience with etanercept in juvenile rheumatoid arthritis.
    Lai JH.
    J Microbiol Immunol Infect; 2005 Dec 16; 38(6):451-4. PubMed ID: 16341348
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Biologic therapy for rheumatoid arthritis.
    Klippel JH.
    N Engl J Med; 2000 Nov 30; 343(22):1640-1. PubMed ID: 11096174
    [No Abstract] [Full Text] [Related]

  • 7. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L, Mouthon L.
    J Rheumatol; 2004 Oct 30; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract] [Full Text] [Related]

  • 8. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis.
    Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, Pontikaki I.
    Arthritis Rheum; 2004 Apr 15; 51(2):301-2. PubMed ID: 15077278
    [No Abstract] [Full Text] [Related]

  • 9. Cutaneous T-cell lymphoma following treatment of rheumatoid arthritis with tumour necrosis factor-alpha blocking agents: two cases.
    Lourari S, Prey S, Livideanu C, Jamard B, Lamant L, Cantagrel A, Paul C.
    J Eur Acad Dermatol Venereol; 2009 Aug 15; 23(8):967-8. PubMed ID: 19192017
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [TNF-alpha inhibitors].
    Fain O.
    Rev Prat; 2003 Nov 30; 53(18):1989-90. PubMed ID: 15008210
    [No Abstract] [Full Text] [Related]

  • 12. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.
    Gerloni V, Pontikaki I, Gattinara M, Fantini F.
    Ann Rheum Dis; 2008 Aug 30; 67(8):1145-52. PubMed ID: 17981916
    [Abstract] [Full Text] [Related]

  • 13. Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
    Passo M.
    Curr Probl Pediatr Adolesc Health Care; 2006 Mar 30; 36(3):97-103. PubMed ID: 16473286
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of tumor necrosis factor inhibitors in patients with RA.
    Trethewey P.
    JAAPA; 2002 Sep 30; 15(9):23-4, 27, 30 passim. PubMed ID: 12395668
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. TNFalpha therapy in psoriatic arthritis and psoriasis.
    Mease P.
    Ann Rheum Dis; 2004 Jul 30; 63(7):755-8. PubMed ID: 15194567
    [No Abstract] [Full Text] [Related]

  • 20. Anti-tumor necrosis factor-alpha agents for rheumatoid arthritis: assessing longterm safety.
    Hyrich KL, Silman AJ.
    J Rheumatol; 2006 May 30; 33(5):831-3. PubMed ID: 16652412
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.